A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor: University of Michigan Rogel Cancer Center
Study ID: NCT02400463
Phase: PHASE2
Status: Completed

Conditions

Hemophagocytic Syndrome (HPS)

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Ruxolitinib — DRUG

Study Details

This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS. The primary endpoint is overall survival at two months.

Key Dates

Start date: Feb 5, 2016
Status verified: Jan 2021
Primary completion: Oct 10, 2019
Completion: Jan 7, 2020

Study Design

Enrollment: 6 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Ruxolitinib
Ruxolitinib 15 mg by mouth twice daily. For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube.

Primary Outcome Measure

Overall Survival at 2 Months [ Time Frame: 2 Months ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	48109	-

Find similar trials in Ann Arbor, MI

By research site

University of Michigan Comprehensive Cancer Center· Ann Arbor, MI